Tratamento do Cancro da Mama HER2-Positivo: Posicionamento de um Painel de Peritos

Abstract

The overexpression of the human epidermal growth factor receptor type 2 (HER2) is present in 20% of all breast cancers and has known prognostic value, associated with a higher risk of recurrence and mortality. Management of these patients has evolved significantly in recent years due to advances in the identification of biomarkers and in treatment efficacy. This article reviews key aspects of the neoadjuvant and adjuvant treatment of early HER2-positive breast cancer, and reflects the opinion of a panel of experts selected by the Portuguese Society of Oncology.
Keywords: Breast Neoplasms/drug therapy; Chemotherapy, Adjuvant; Neoadjuvant Therapy; Receptor, ErbB-2.